Cite
HARVARD Citation
Fizazi, K. et al. (2019). Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet oncology. 20 (5), pp. 686-700. [Online].